NASDAQ:NVCR Novocure Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novocure Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $104.15 -0.96 (-0.91 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$100.13Now: $104.15▼$105.6150-Day Range$74.54MA: $84.50▼$110.7452-Week Range$53.40Now: $104.15▼$110.98Volume1.06 million shsAverage Volume1.01 million shsMarket Capitalization$10.53 billionP/E Ratio867.99Dividend YieldN/ABeta1.59 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.Read More Beat the Market (BTM) Rank™ 2.1 Analyst's Opinion Consensus RatingNovocure has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $90.67, Novocure has a forecasted downside of 12.8% from its current price of $104.03.Amount of Analyst CoverageNovocure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesNovocure has received 423 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovocure has received 408 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovocure has received 50.90% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote “Outperform” if you believe NVCR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovocure does not currently pay a dividend.Dividend GrowthNovocure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novocure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,602,582.00 in company stock.Percentage Held by InsidersOnly 5.07% of the stock of Novocure is held by insiders.Percentage Held by Institutions67.57% of the stock of Novocure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Novocure are expected to grow by 80.00% in the coming year, from $0.20 to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novocure is 866.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Novocure is 866.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.61.Price to Book Value per Share RatioNovocure has a P/B Ratio of 47.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR Previous Symbol CUSIPN/A CIK1645113 Webwww.novocure.com Phone44-0-15-3475-6700Debt Debt-to-Equity Ratio0.61 Current Ratio5.73 Quick Ratio5.42Price-To-Earnings Trailing P/E Ratio867.99 Forward P/E Ratio520.75 P/E GrowthN/A Sales & Book Value Annual Sales$351.32 million Price / Sales29.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book47.34Profitability EPS (Most Recent Fiscal Year)($0.07) Net Income$-7,230,000.00 Net Margins2.88% Return on Equity5.14% Return on Assets2.41%Miscellaneous EmployeesN/A Outstanding Shares101,091,000Market Cap$10.53 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $104.15 -0.96 (-0.91 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NVCR News and Ratings via Email Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Novocure (NASDAQ:NVCR) Frequently Asked Questions How has Novocure's stock price been impacted by Coronavirus? Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 54.6% and is now trading at $104.15. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Novocure? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novocure. When is Novocure's next earnings date? Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for Novocure. How were Novocure's earnings last quarter? Novocure Ltd (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, July, 30th. The medical equipment provider reported $0.02 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.01. The medical equipment provider earned $115.90 million during the quarter, compared to analyst estimates of $105.96 million. Novocure had a return on equity of 5.14% and a net margin of 2.88%. Novocure's revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.01) EPS. View Novocure's earnings history. What price target have analysts set for NVCR? 9 brokerages have issued 12-month target prices for Novocure's shares. Their forecasts range from $58.00 to $125.00. On average, they anticipate Novocure's stock price to reach $90.67 in the next year. This suggests that the stock has a possible downside of 12.9%. View analysts' price targets for Novocure. Who are some of Novocure's key competitors? Some companies that are related to Novocure include Baxter International (BAX), DexCom (DXCM), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Nevro (NVRO), Globus Medical (GMED), Haemonetics (HAE) and ICU Medical (ICUI). View all competitors. What other stocks do shareholders of Novocure own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), NVIDIA (NVDA), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), salesforce.com (CRM) and Square (SQ). Who are Novocure's key executives? Novocure's management team includes the following people: Asaf Danziger, Chief Executive Officer & DirectorMike Ambrogi, Chief Operating OfficerWilco Groenhuysen, CFO & Chief Accounting OfficerEilon D. Kirson, Chief Science Officer, Head-Research & DevelopmentUri Weinberg, Vice President-Clinical Development What is Novocure's stock symbol? Novocure trades on the NASDAQ under the ticker symbol "NVCR." Who are Novocure's major shareholders? Novocure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (10.33%), Vanguard Group Inc. (7.39%), Macquarie Group Ltd. (0.93%), Two Sigma Advisers LP (0.88%), Mitsubishi UFJ Trust & Banking Corp (0.55%) and Rhenman & Partners Asset Management AB (0.37%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends for Novocure. Which major investors are selling Novocure stock? NVCR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., Frontier Capital Management Co. LLC, Healthcare of Ontario Pension Plan Trust Fund, Nicholas Investment Partners LP, and American International Group Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle. View insider buying and selling activity for Novocure. Which major investors are buying Novocure stock? NVCR stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Two Sigma Advisers LP, Cubist Systematic Strategies LLC, C WorldWide Group Holding A S, Canada Pension Plan Investment Board, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for Novocure. How do I buy shares of Novocure? Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Novocure's stock price today? One share of NVCR stock can currently be purchased for approximately $104.15. How big of a company is Novocure? Novocure has a market capitalization of $10.53 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. What is Novocure's official website? The official website for Novocure is www.novocure.com. How can I contact Novocure? Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
